1.
Rev. méd. Chile
;
143(7): 895-904, jul. 2015. tab
Article
Dans Espagnol
| LILACS
| ID: lil-757915
Résumé
Therapy for submassive pulmonary embolism (intermediate risk), remains controversial. New evidence has appeared that may help us in the process of decision making. We review the relevant literature, outline prognostic factors, and discuss current recommendations and controversies regarding the available alternatives such as systemic and catheter-directed thrombolytic use.